Alternating two pills plus bevacizumab for advanced colon cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests a treatment plan that alternates two cancer pills and adds bevacizumab (a blood-vessel drug) for metastatic colon cancer that has come back or worsened after standard treatment. It may help shrink tumors and slow disease growth after later-line therapy options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV (metastatic) colon cancer confirmed by lab testing, and it has worsened after standard treatments like 5-FU, irinotecan, and oxaliplatin
- You have documentation that your most recent scan showed progression (new/worsening cancer)
- Your cancer has measurable disease that can be measured on scans or exams
- You are at least 18 years old, and your overall daily functioning is good (ECOG 0–1)
- Your blood counts and liver function are within required limits (enough white cells, platelets, hemoglobin, and acceptable AST/ALT)
- You can take pills by mouth (no feeding tube) and can follow study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
This trial is for people with advanced colorectal cancer who are unable to receive standard combination chemotherapy. It tests a combination of two drugs, TAS-102 and bevacizumab, as the first treatment for their condition. The goal is to see if this combination can help slow the growth of the cancer and improve quality of life.
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
This trial tests whether adding a drug called bevacizumab (which helps stop blood vessel growth to tumors) to a combination of two chemotherapy drugs (oxaliplatin and TAS-102) can help people with advanced colorectal cancer. It is for people who have not yet received treatment for their advanced cancer.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.